Ultrasound-Guided Biopsy

PROCEDURE4 trials

Sponsors

M.D. Anderson Cancer Center, Mayo Clinic, University of Washington

Conditions

Advanced CholangiocarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast CancerLocally Advanced Breast CarcinomaMetastatic CholangiocarcinomaMetastatic Triple-Negative Breast CarcinomaRefractory Cholangiocarcinoma

Phase 1

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

TerminatedNCT06420349

Mayo ClinicAdvanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma +4

Start: 2024-05-31End: 2025-09-09Updated: 2025-12-22

Phase 2

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

RecruitingNCT07078604

University of WashingtonAnatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

Start: 2026-04-11End: 2028-06-30Target: 20Updated: 2026-03-12

Unknown Phase

Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery

Active, not recruitingNCT02455791

M.D. Anderson Cancer CenterBreast Cancer

Start: 2015-06-24End: 2026-12-31Updated: 2026-03-09

Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer

SuspendedNCT05547347

Mayo ClinicAnatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Resectable Breast Carcinoma

Start: 2023-03-21End: 2026-12-31Target: 15Updated: 2026-03-31

Related Papers

A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinoma

Future Oncology2025-07-282 citations